Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

Roche’s Avastin gains Japanese approval for brain cancer

Marks drug's first approval to treat newly diagnosed glioblastoma

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Electronic medical records ‘could boost clinical trial efficiency’

Quicker recruitment times and lower development costs among potential benefits, says Parexel

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

- PMLiVE

GSK fires senior Chinese scientist over data fabrication

Pharma company dismisses head of Chinese R&D unit after tip-off about inaccurate MS data in journal

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

Ben Goldacre: No escape from trial transparency

Bad Pharma author says AllTrials and new European legislation make data disclosure unavoidable

Roche - Basel

EU approves new use of Roche’s RoActemra in children

Swiss pharma firm hopes to increase revenue from arthritis drug to tip it into blockbuster status

- PMLiVE

Boehringer says faldaprevir does well in Asian hepatitis C patients

Trial success in patients from Korea, Japan and Taiwan

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

Boehringer invests €35m in research centre in China

Teams up with Shanghai firm to build biopharma facility

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links